Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLG) Liabilities and Shareholders Equity (2016 - 2025)

Bone Biologics has reported Liabilities and Shareholders Equity over the past 3 years, most recently at $795659.0 for Q4 2017.

  • Quarterly Liabilities and Shareholders Equity rose 13.48% to $795659.0 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Dec 2017, down 38.13% year-over-year, with the annual reading at $795659.0 for FY2017, 13.48% up from the prior year.
  • Liabilities and Shareholders Equity was $795659.0 for Q4 2017 at Bone Biologics, down from $1.7 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $4.3 million in Q1 2016 and troughed at $701140.0 in Q4 2016.
  • The 3-year median for Liabilities and Shareholders Equity is $1.5 million (2015), against an average of $1.6 million.
  • The largest YoY upside for Liabilities and Shareholders Equity was 116.3% in 2017 against a maximum downside of 62.79% in 2017.
  • A 3-year view of Liabilities and Shareholders Equity shows it stood at $1.5 million in 2015, then tumbled by 54.67% to $701140.0 in 2016, then grew by 13.48% to $795659.0 in 2017.
  • Per Business Quant, the three most recent readings for BBLG's Liabilities and Shareholders Equity are $795659.0 (Q4 2017), $1.7 million (Q3 2017), and $868389.0 (Q2 2017).